Stopping GLP-1 Drugs May Raise Heart Disease Risk, Study Finds

Stopping popular GLP-1 medications, widely used for type 2 diabetes and weight loss, may significantly raise heart disease risk, according to a new large study. Drugs such as semaglutide and tirzepatide have surged in popularity, with about one in eight U.S. adults having taken them. These medications not only lower blood sugar and support weight loss but also deliver key cardiovascular benefits. However, research from Washington University School of Medicine in St. Louis, published in BMJ Medicine, warns that discontinuation can lead to rapid loss of these protections.

Background on GLP-1 Medications and Heart Health

GLP-1 receptor agonists, or GLP-1 drugs, mimic the glucagon-like peptide-1 hormone to regulate blood sugar, reduce appetite, and promote weight loss. Beyond diabetes management, they improve heart disease risk factors by lowering blood pressure, reducing inflammation, and optimizing cholesterol levels. This makes them valuable for patients with type 2 diabetes, who face elevated risks of heart attacks, strokes, and cardiovascular death.

Semaglutide (found in Ozempic and Wegovy) and tirzepatide (in Mounjaro and Zepbound) are among the most prescribed. Millions use them, but real-world adherence varies due to side effects like nausea, high costs, or supply issues. Understanding the consequences of stopping GLP-1 drugs is crucial for patients and clinicians aiming to sustain metabolic health.

The Landmark Study: Methods and Key Findings

The study analyzed data from more than 333,000 U.S. veterans with type 2 diabetes, followed for up to three years. Researchers compared continuous GLP-1 users, those who stopped or interrupted treatment, and those on sulfonylureas—a common alternative diabetes drug.

Continuous Use Delivers Strong Protection

Individuals who continuously took GLP-1 medications for the full three years had the lowest risk of major cardiovascular events—heart attacks, strokes, and death. Their risk was reduced by about 18%, equating to roughly four fewer serious events per 100 people over three years compared to sulfonylurea users.

Risks Rise Quickly After Stopping

Benefits faded rapidly upon discontinuation. Even a six-month break linked to higher risk versus continuous use. Interruptions followed by restarts did not fully restore protection. Longer gaps worsened outcomes:

• One-year stop: Much higher risk of serious heart problems.
• Two-year stop: Up to 22% increased risk compared to continuous users.

About one-quarter of participants stopped GLP-1 drugs entirely, and nearly another quarter had long interruptions, reflecting common real-world challenges.

Time-Dependent Benefits

Protection built gradually; users on GLP-1s for over 18 months gained more benefits than short-term users who stopped. Those with less than 18 months of use showed no significant long-term edge over sulfonylurea users.

How GLP-1 Drugs Protect the Heart: Mechanisms Explained

GLP-1 medications influence multiple pathways. They enhance insulin secretion while suppressing glucagon, stabilizing blood sugar. Weight loss reduces cardiac strain, while direct effects slow atherosclerosis by curbing inflammation and improving endothelial function. Blood pressure drops due to vasodilation, and lipid profiles improve with lower triglycerides and better HDL.

Stopping triggers "metabolic whiplash," per researchers: Blood pressure, cholesterol, and inflammation rebound, even if not immediately noticeable. This reversal heightens vulnerability to plaques rupturing or clots forming, explaining the study's observed risks.

Restarting helps but offers less robust protection, suggesting possible lasting vascular changes from interruptions.

Implications for Patients with Type 2 Diabetes

For the estimated 38 million Americans with type 2 diabetes, these findings underscore GLP-1 drugs as long-term therapies, not short-term weight-loss aids. Patients considering semaglutide or tirzepatide should discuss adherence strategies with providers.

Who Might Benefit Most? Those with obesity, hypertension, or prior cardiovascular events. Continuous use maximizes heart protection alongside glycemic control.

Practical Guidance:

• Track symptoms and side effects using apps like Shotlee to identify issues early and stay adherent.
• Explore cost-saving options like manufacturer savings cards or generics where available.
• Combine with lifestyle changes—diet, exercise—for sustained results.

Consult doctors before stopping; abrupt halts risk not just heart issues but also blood sugar spikes or weight regain.

Challenges to Continuous GLP-1 Use and Solutions

High costs (often $1,000+ monthly without insurance), gastrointestinal side effects, and shortages drive discontinuations. About 25% quit outright, per the study.

Solutions include:

• Side Effect Management: Start low doses, titrate slowly; anti-nausea meds if needed.
• Access Support: Patient assistance programs, telehealth for prescriptions.
• Monitoring Tools: Digital trackers for medication schedules and vitals.

Healthcare systems should prioritize adherence support to preserve GLP-1 benefits.

Study Strengths, Limitations, and Comparisons

This observational study excels in scale (333,000 participants) and duration (up to 3 years), revealing real-world patterns. It compared GLP-1s directly to sulfonylureas, which lack similar cardiovascular data.

Limitations: Focused on U.S. veterans (mostly male, older), potentially less generalizable. Observational design shows associations, not causation—though consistent trends strengthen credibility.

Vs. alternatives: Sulfonylureas risk hypoglycemia without heart benefits; other GLP-1s like liraglutide show similar profiles in trials like LEADER.

Key Takeaways: What This Means for Heart Health

• Continuous GLP-1 use cuts major cardiovascular risk by ~18% over 3 years.
• Stopping—even briefly—increases heart attack, stroke, and death risk, up to 22% after 2 years off.
• Benefits accrue over time; treat as chronic therapy.
• Restarts help but don't fully recover lost protection.
• Address barriers proactively for optimal outcomes.

Conclusion: Prioritizing Long-Term Adherence

GLP-1 medications like semaglutide and tirzepatide offer substantial heart health advantages for type 2 diabetes patients, but only with sustained use. The Washington University study in BMJ Medicine highlights that stopping GLP-1 drugs may raise heart disease risk through metabolic reversals. Patients should partner with providers to overcome hurdles, ensuring these drugs fulfill their potential as lifelong allies in metabolic and cardiovascular care. Discuss your regimen today to safeguard your heart.